SAN ANTONIO, USA—Women with hormone receptor positive HER-2 negative breast cancer and Oncotype DX recurrence scores above 31 could benefit from having anthracycline therapy added to their taxane-based chemotherapy, according to breast medical oncologist and assistant professor of internal medicine, Nan Chen MD, from the University of Chicago. She reported her group’s latest analysis of records from 2,528 patients in the TAILORx trial at the 2024 San Antonio Breast Cancer Symposium comparing patients being treated after surgery with taxane/cyclophosphamide chemotherapy with or without addition ..read more

SAN FRANCISCO, CA—Adding the poly ADP ribose polymerase (PARP) inhibitor drug talazoparib to standard anti-androgen therapy with enzalutamide statistically significantly extended overall survival among patients whose metastatic castration resistant prostate cancers had specific molecular markers. This finding was reported at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium held in San Francisco from the TALAPRO-2 phase three clinical trial investigating patients with or without homologous recombination repair (HRR) gene alterations. The co-lead author of th ..read more

Audio Journal of Oncology Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab LOS ANGELES, CA—Single agent immunotherapy with the anti-programmed death-1 (PD-1) agent pembrolizumab resulted in markedly high melanoma-specific survival rates among patients with either resectable or metastatic desmoplastic melanoma in a study reported to the American Association for Cancer Research 2025 Immno Oncology conference. Lead researcher Kari L Kendra MD PhD, Director of the Cutaneous Oncology Program and Chair of the Melanoma Disease Specific Committee at Ohio St ..read more

Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer The important question of whether to recommend risk-reducing surgery to patients who are carriers of pathogenic mutations in either BRCA1 or BRCA2 genes (or both), and have already developed breast cancer, has been investigated in a study from Italy reported at the 2025 San Antonio Breast Cancer Symposium. Researcher Matteo Lambertini MD PhD, from the University of Genoa, Assistant Professor and Consultant in Medical Oncology at the San Martino IST Hospital in G ..read more

SAN ANTONIO, USA—In patients with hormone receptor-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS) active monitoring, compared with surgery, resulted in no difference in terms of cancer outcomes in the multicenter, randomized COMET study that compared oncologic outcomes of patients randomized to guideline-concordant care (with surgery alone or with radiation therapy) or active monitoring. COMET investigated 995 patients with grade one or two DCIS with no evidence of invasive cancer. After reporting the findings at the 2024 San Antonio Breast Cancer Symposium, study author E ..read more

SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium from the BIG 2-04 MRC SUPREMO international phase three randomized controlled trial. At the conference Ian Kunkler MA, MB, BChir, Professor at Edinburgh Cancer Centre in the Western General Hospital, University of Edinburgh, Scotland UK, told the conference that after investigating the impact of adjuvant chest wall irradiation following mastectomy and axillary surgical staging in patients with opera ..read more

SAN DIEGO, USA—A higher intake of dietary fiber after allogeneic hematopoietic cell transplantation was associated with increased overall survival, a lower incidence of graft-versus-host disease, an increase in fecal concentrations of beneficial short-chain fatty acids and greater microbial diversity of the gut microbiome.  These findings came from a study with 173 patients led by Jenny Paredes PhD, of the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope National Medical Center in Duarte, California, and were reported at the 2024 Annual Meeting of the Americ ..read more

SAN DIEGO, USA—When added to standard chemotherapy the bi-specific T-cell engager drug blinatumomab brought a large, statistically significant improvement in disease-free survival in a randomized controlled study of 1731 children with average or higher relapse-risk B-cell acute lymphoblastic leukemia. Study first author Rachel E. Rau MD, from the Seattle Children’s Hospital, University of Washington, in the USA, reported her group’s findings at the 2024 Annual Meeting of the American Society of Hematology in San Diego. Hot from the conference she gave the details to Audio Journal of Oncology r ..read more

SAN DIEGO, USA—When added to standard chemotherapy the bi-specific T-cell engager drug blinatumomab brought a large, statistically significant improvement in disease-free survival in a randomized controlled study of 1731 children with average or higher relapse-risk B-cell acute lymphoblastic leukemia. Study first author Rachel E. Rau MD, from the Seattle Children’s Hospital, University of Washington, in the USA, reported her group’s findings at the 2024 Annual Meeting of the American Society of Hematology in San Diego. Hot from the conference she gave the details to Audio Journal of Oncology r ..read more

https://www.audiomedica.com/wp-content/2024/12/241208-Hua-Zhang-MD-PhD-ASH-2024-22Double-Edge-CAR-T-Therapy-for-RR-CLL22-AJO-MONO-AUDIO-MASTER.mp3 https://www.audiomedica.com/wp-content/2024/12/241208-Hua-Zhang-MD-PhD-ASH-2024-22Double-Edge-CAR-T-Therapy-for-RR-CLL22-AJO-MONO-AUDIO-MASTER.mp3 Audio Journal of Oncology Podcast December, 2024:   Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia   Hua Zhang MD PhD (Chief Scientific Officer with SPH Biotherapeutics Limited, Shanghai and Hong Kong, China) tells the Audio Journal abou ..read more